Perioperative immune modulation in renal cell carcinoma - Review of the current situation;Perioperative immunmodulation beim nierenzellkarzinom - Eine standortbestimmung

Aktuelle Urologie

Volumn 34, Issue 5, 2003, Pages 319-327

  Böhm, Malte ^a   Klatte, T ^a   Allhoff, E P ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Immunomodulation; Interleukin 2; Perioperative; Renal cancer

Indexed keywords

ALPHA INTERFERON; CIMETIDINE; CONSENSUS INTERFERON; CYCLOPHOSPHAMIDE; GLUTAMINE; LENTINAN; PACLITAXEL; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; FEVER; HUMAN; HUMORAL IMMUNITY; HYPERTHERMIA; IMMUNOMODULATION; IMMUNOPATHOLOGY; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; PERIOPERATIVE PERIOD; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY; SURVIVAL RATE;

EID: 18844482434     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-42008     Document Type: Review

References (56)

1. Hermanek P, Schrott KM. Evaluation of the new tumor, nodes and metastasis classification of renal cell carcinoma. J Urol 1990; 144: 238-242
2. Carl P, Klein U, Gebauer A, Schmiedt E. The value of lymphography for the TNM classification of renal carcinoma. Eur Urol 1977; 3: 286-288
3. Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990; 143: 468-474
4. Sánchez de la Muela P, Zudaire JJ, Robles JE, Rosell D, Aguera L, De Castro F, Isa W, Berián JM. Renal cell carcinoma: vena caval invasion and prognostic factors. Eur Urol 1991; 19: 284-290
5. Herrlinger A, Schrott KM, Schott G, Sigel A. What are the benefits of extended dissection of the regional lymph nodes in the therapy of renal cell carcinoma? J Urol 1991; 146: 1224-1227
6. Eschwege P, Saussine C, Steichen G, Delepaul B, Drelon L, Jacqmin D. Radical nephrectomy for renal cell carcinoma 30 mm or less: long-term follow results. J Urol 1996; 155: 1196-1199
7. Takashi M, Takagi Y, Sakata T, Shimoji T, Miyake K. Clinicopathological characteristics of small renal cell carcinomas. Int Urol Nephrol 1994; 26: 621-629
8. Siminovitch JP, Montie JE, Straffon RA. Lymphadenectomy in renal adenocarcinoma. J Urol 1982; 127: 1090-1091
9. Hultén L, Rosencrantz M, Seeman T, Wahlqvist L, Åhrén C. Occurrence and localization of lymph node metastases in renal carcinoma. Scand J Urol Nephrol 1969; 3: 129-133
10. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101: 297-301
11. Parry-Billings M, Baigrie RJ, Lamont PM, Morris PJ, Newsholme EA. Effects of major and minor surgery on plasma glutamine and cytokine levels. Arch Surg 1992; 127: 1237-1240
12. Hensler T, Hecker H, Heeg K, Heidecke C-D, Bartels H, Barthlen W, Wagner H, Siewert JR, Holzmann B. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun 1997; 65: 2283-2291
13. Allendorf JD, Bessler M, Whelan RL, Trokel M, Laird DA, Terry MB, Treat MR. Postoperative immune function varies inversely with the degree of surgical trauma in a murine model. Surg Endosc 1997; 11: 427-430
14. Kuntz C, Wunsch A, Bay F, Windeler J, Glaser F, Herfarth C. Prospective randomized study of stress and immune response after laparoscopic vs. conventional colonic resection. Surg Endosc 1998; 12: 963-967
15. Gitzelmann CA, Mendoza-Sagaon M, Talamini MA, Ahmad SA, Pegoli WJ, Paidas CN. Cell-mediated immune response is better preserved by laparoscopy than laparotomy. Surgery 2000; 127: 65-71
16. Ogawa K, Hirai M, Katsube T, Murayama M, Hamaguchi K, Shimakawa T, Naritake Y, Hosokawa T, Kajiwara T. Suppression of cellular immunity by surgical stress. Surgery 2000; 127: 329-336
17. Leaver HA, Craig SR, Yap PL, Walker WS. Lymphocyte responses following open and minimally invasive thoracic surgery. Eur J Clin Invest 2000; 30: 230-238
18. Böhm M, Ittenson A, Philipp C, Röhl F-W, Ansorge S, Allhoff EP. Complex perioperative immunodysfunction in patients with renal cell carcinoma. J Urol 2001; 166: 831-836
19. Ashida S, Okuda H, Chikazawa M, Tanimura M, Sugita O, Yamamoto Y, Nakamura S, Moriyama M, Shuin T. Detection of circulating cancer cells with von Hippel-Lindau gene mutation in peripheral blood of patients with renal cell carcinoma. Clin Cancer Res 2000; 6: 3817-3822
20. McKiernan JM, Buttyan R, Bander NH, de-la-Taille A, Stifelman MD, Emanuel ER, Bagiella E, Rubin MA, Katz AE, Olsson CA, Sawczuk IS. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer 1999; 86: 492-497
21. Bilkenroth U, Taubert H, Riemann D, Rebmann U, Heynemann H, Meye A. Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunogenetic cell separation. Int J Cancer 2001; 92: 577-582
22. Thèze J. The cytokine network and immune functions. New York: Oxford University Press, 1999
23. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunther 2001; 24: 392-407
24. Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology. Philadelphia: Saunders, 2000
25. Smith KA. IL-2. In: Oppenheim JJ, Feldman M (Hrsg.). Cytokine reference. London: Academic Press, 2001: 113-126
26. Civallero M, Barni S, Nano R, Capelli E. Dendritic cells and interleukin-2: cytochemical and ultrastructural study. Histol Histopathol 2000; 15: 1077-1085
27. Schnurr M, Galambos P, Scholz C, Dauer M, Krug A, Hartmann G, Eigler A, Endres S. Deutsches Ärzteblatt 2002; 99: A2408-A2416
28. Overwijk WW, Theoret MR, Restifo NP. The future of Interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci AM 2000; 6 Suppl 1: S76-S80
29. Hoffman DM, Figlin RA. Intratumoral interleukin-2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol 2000; 18: 152-156
30. Larchian WA, Horiguchi Y, Nair SK, Fair WR, Heston WD, Gilboa E. Effectiveness of combined Interleukin-2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Clin Cancer Res 2000; 6: 2913-2920
31. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes. Science 2002; 298: 850-854
32. Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res 2001; 7: 2862-2869
33. Nichols PH, Ramsden CW, Ward U, Sedman PC, Primrose JN. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res 1992; 52: 5765-5769
34. Nichols PH, Ramsden CW, Ward U, Trejdosiewicz LK, Ambrose NS, Primrose JN. Perioperative modulation of cellular immunity in patients with colorectal cancer. Clin Exp Immunol 1993; 94: 4-10
35. Deehan DJ, Heys SD, Simpson W, Broom J, McMillan DN, Eremin O. Modulation of the cytokine and acute-phase response to major surgery by recombinant interleukin-2. Br J Surg 1995; 82: 86-90
36. Böhm M, Ittenson A, Schierbaum KF, Röhl F-W, Ansorge S, Allhoff EP. Petreatment with interleukin-2 (IL-2) attenuates perioperative immunodysfunction in patients with renal cell carcinoma. Eur Urol 2002; 41: 458-468
37. Brivio F, Lissoni P, Alderi G, Barni S, Lavorato F, Fumagalli L. Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advances colorectal cancer patients. Oncology 1996;53: 263-268
38. Brivio F, Brivio O, Lissoni P, Emanuelli G, Girlando M, Uggeri F, Presurgical neuroimmunotherapy with melatonin and interleukin-2 in cancer patients. In: Maestroni GJM, Conti A, Reiter RJ (Hrsg.). Therapeutic potential of melatonin. Front Horm Res. Basel: Karger, 1997: 137-148
39. Masotti A, Morandini G, Ortolani R, Fumagalli L. Phase-II randomized study of preoperative IL-2 administration in operable NSCLC. Lung Cancer 1998; 20: 191-202
40. De Maeyer E, De Maeyer-Guignard J. Type I interferons. In: Bona CA, Revillard J-P (Hrsg.). Cytokines and cytokine receptors: physiology and pathological disorders. Amsterdam: Harwood Academic Publishers, 2000: 316-333
41. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998; 161: 1947-1953
42. Sedman PC, Ramsden CW, Brennan TG, Giles GR, Guillou PJ. Effects of low dose perioperative interferon on the surgically induced suppression of antitumour immune responses. Br J Surg 1988; 75: 976-981
43. Fujioka T, Yoshida N, Hasegawa M, Ishikura K, Suzuki Y, Kubo T. Interleukin-2 expanded tumor-infiltrating lymphocytes and their response to preoperative α-interferon in patients with renal cell carcinoma. J Urol 1994; 152: 852-856
44. Houvenaeghel G, Bladou F, Blache JL, Olive D, Monges D, Jacqnemier J, Chaudet H, Delpero JR, Guerinel G. Tolerance and feasibility of perioperative treatment with interferon-α2a in advanced cancers. Int Surg 1997; 82: 165-169
45. Sejima T, Miyagawa I. The evaluation of Fas/Fas ligand system in renal cell carcinoma - the effect of preoperative interferon-α therapy. Nippon Hinyokika Gakkai Zasshi 1999; 90: 826-832
46. Nielsen HJ, Pedersen BK, Moesgaard F, Haahr PM, Kehlet H. Effect of ranitidine on postoperative suppression of natural killer cell activity and delayed hypersensitivity. Acta Chir Scand 1989; 155: 377-382
47. Katoh J, Tsuchiya K, Osawa H, Sato W, Matsumura G, Iida Y, Suzuki S, Hosaka S, Yoshii S, Tada Y. Cimetidine reduces impairment of cellular immunity after cardiac operations with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998; 116: 312-318
48. O'Riordain MG, Fearon KC, Ross JA, Rogers P, Falconer JS, Bartolo DC, Garden OJ, Carter DC. Glutamine-supplemented total parenteral nutrition enhances T-lymphocyte response in surgical patients undergoing colorectal resection. Ann Surg 1994; 220: 212-221
49. Kerrebijn JD, Simons PJ, Balm AJ, Tas M, Knegt PP, de Vries N, Tan IB, Drexhage HA. Thymostimulin enhancement of T-cell infiltration into head and neck squamous cell carcinoma. Head Neck 1996; 18: 335-342
50. Hamano K, Gohra H, Katoh T, Fujimura Y, Zempo N, Esato K. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. Int J Immunopharmacol 1999; 21: 531-540
51. Hubel K, Mansmann G, Schafer H, Oberhauser F, Diehl V, Engert A. Increase of antiinflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF. Cytokine 2000; 12: 1797-1800
52. Bex A, Horenblas S, Meinhardt W, Verra N, de Gast GC. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol 2002; 42: 570-576
53. Morris KT, Johnson N, Homer L, Walts D. A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 2000; 179: 407-411
54. Oz MC, Whitworth GC, Liu EH. Complementary medicine in the surgical wards. JAMA 1998; 279: 710-711
55. Fair WR. Back to the future - the role of complementary medicine in urology. J Urol 1999; 162: 411-420
56. Bruss K, Salter C, Galán E. American Cancer Society's guide to complementary and alternative cancer methods. Atlanta: American Cancer Society, 2000